{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T23:48:34Z","timestamp":1793490514727,"version":"4.5.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart Lung and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Advances"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jacadv.2026.103096","type":"journal-article","created":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T21:04:12Z","timestamp":1785963852000},"page":"103096","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Prediabetes, Malignant Left Ventricular Hypertrophy, and Risk of Incident Heart Failure Among Hypertensive Adults"],"prefix":"10.1016","volume":"5","author":[{"given":"Arnaud D.","family":"Kaze","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen P.","family":"Juraschek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4649-079X","authenticated-orcid":false,"given":"Jordana B.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Zawaneh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiadi E.","family":"Ndumele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christie M.","family":"Ballantyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jarrett D.","family":"Berry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8460-1617","authenticated-orcid":false,"given":"Justin B.","family":"Echouffo-Tcheugui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacadv.2026.103096_bib1","first-page":"e41","article-title":"2025 heart disease and stroke statistics: a report of US and global data from the American Heart Association","volume":"151","author":"Martin","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.jacadv.2026.103096_bib2","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1016\/j.jacc.2019.02.042","article-title":"Disparities in cardiovascular mortality related to heart failure in the United States","volume":"73","author":"Glynn","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacadv.2026.103096_bib3","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/j.cardfail.2023.07.006","article-title":"Heart failure epidemiology and outcomes statistics: a report of the Heart Failure Society of America","volume":"29","author":"Bozkurt","year":"2023","journal-title":"J Card Fail"},{"key":"10.1016\/j.jacadv.2026.103096_bib4","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1161\/CIRCULATIONAHA.105.558734","article-title":"The transition from hypertrophy to failure: how certain are we?","volume":"112","author":"Drazner","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.jacadv.2026.103096_bib5","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1161\/CIRCULATIONAHA.108.845792","article-title":"The progression of hypertensive heart disease","volume":"123","author":"Drazner","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.jacadv.2026.103096_bib6","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1161\/HYPERTENSIONAHA.118.11125","article-title":"Myocardial remodeling in hypertension","volume":"72","author":"Gonz\u00e1lez","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.jacadv.2026.103096_bib7","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.numecd.2018.07.005","article-title":"Diabetes mellitus, blood glucose and the risk of heart failure: a systematic review and meta-analysis of prospective studies","volume":"28","author":"Aune","year":"2018","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.jacadv.2026.103096_bib8","first-page":"136","article-title":"Impact of diabetes on epidemiology, treatment, and outcomes of patients with heart failure. JACC","volume":"3","author":"Dei Cas","year":"2015","journal-title":"Heart Fail"},{"key":"10.1016\/j.jacadv.2026.103096_bib9","series-title":"Diabetes, cardiomyopathy, and heart failure","author":"Oktay","year":"2000"},{"key":"10.1016\/j.jacadv.2026.103096_bib10","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1111\/dom.14388","article-title":"Prediabetes and the risk of heart failure: a meta-analysis","volume":"23","author":"Cai","year":"2021","journal-title":"Diabetes. Obes Metab"},{"key":"10.1016\/j.jacadv.2026.103096_bib11","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1001\/jama.2015.10029","article-title":"Prevalence of and trends in diabetes among adults in the United States, 1988-2012","volume":"314","author":"Menke","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.jacadv.2026.103096_bib12","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1056\/NEJM199012133232413","article-title":"Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study","volume":"323","author":"Manyari","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacadv.2026.103096_bib13","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1161\/01.CIR.103.19.2346","article-title":"Echocardiographic and electrocardiographic diagnoses of left ventricular hypertrophy predict mortality independently of each other in a population of elderly men","volume":"103","author":"Sundstr\u00f6m","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.jacadv.2026.103096_bib14","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1161\/hc4201.097944","article-title":"Left ventricular hypertrophy as an independent predictor of acute cerebrovascular events in essential hypertension","volume":"104","author":"Verdecchia","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.jacadv.2026.103096_bib15","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1093\/ajh\/hpx067","article-title":"Electrocardiographic left ventricular hypertrophy predicts cardiovascular morbidity and Mortality in Hypertensive Patients: the ALLHAT study","volume":"30","author":"Bang","year":"2017","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.jacadv.2026.103096_bib16","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jacc.2012.10.012","article-title":"Biomarkers of chronic cardiac injury and hemodynamic stress identify a malignant phenotype of left ventricular hypertrophy in the general population","volume":"61","author":"Neeland","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacadv.2026.103096_bib17","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1001\/jamacardio.2018.4300","article-title":"Association of cardiac injury and malignant left ventricular hypertrophy with risk of heart failure in African Americans: the Jackson heart Study","volume":"4","author":"Pandey","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacadv.2026.103096_bib18","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.jchf.2014.12.018","article-title":"Older adults, \u201cMalignant\u201d left ventricular hypertrophy, and associated cardiac-specific biomarker phenotypes to identify the differential risk of new-onset reduced versus preserved ejection fraction heart failure: CHS (Cardiovascular Health Study)","volume":"3","author":"Seliger","year":"2015","journal-title":"JACC. Heart Fail"},{"key":"10.1016\/j.jacadv.2026.103096_bib19","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1373\/clinchem.2013.203638","article-title":"Troponin T and N-terminal pro-B-type natriuretic peptide: a biomarker approach to predict heart failure risk--the atherosclerosis risk in communities study","volume":"59","author":"Nambi","year":"2013","journal-title":"Clin Chem"},{"key":"10.1016\/j.jacadv.2026.103096_bib20","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1161\/CIRCULATIONAHA.124.069735","article-title":"NT-proBNP and cardiac Troponin I, but not cardiac Troponin T, are associated with 7-Year changes in cardiac structure and function in older adults: the ARIC study","volume":"150","author":"Myhre","year":"2024","journal-title":"Circulation"},{"issue":"17","key":"10.1016\/j.jacadv.2026.103096_bib21","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA Guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacadv.2026.103096_bib22","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1177\/1740774514537404","article-title":"The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT)","volume":"11","author":"Ambrosius","year":"2014","journal-title":"Clin Trials"},{"key":"10.1016\/j.jacadv.2026.103096_bib23","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","article-title":"A randomized trial of intensive versus standard blood-pressure control","volume":"373","author":"Wright","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacadv.2026.103096_bib24","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1001\/jamacardio.2021.3187","article-title":"Associations of high-sensitivity troponin and natriuretic peptide levels with outcomes after intensive blood pressure lowering: findings from the SPRINT randomized clinical trial","volume":"6","author":"Berry","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacadv.2026.103096_bib25","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1093\/clinchem\/hvad209","article-title":"High-Sensitivity Cardiac troponins I and T and cardiovascular outcomes: findings from the systolic blood pressure intervention trial (SPRINT)","volume":"70","author":"Jia","year":"2024","journal-title":"Clin Chem"},{"key":"10.1016\/j.jacadv.2026.103096_bib26","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1002\/ejhf.3447","article-title":"Metabolic dysfunction and incidence of heart failure subtypes among black individuals: the Jackson Heart Study","volume":"27","author":"Kaze","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacadv.2026.103096_bib27","doi-asserted-by":"crossref","first-page":"464","DOI":"10.2337\/dc24-0654","article-title":"Diabetes, subclinical myocardial injury or stress, and risk of heart failure subtypes: the Jackson Heart Study","volume":"48","author":"Kaze","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacadv.2026.103096_bib28","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1016\/j.jacc.2022.08.735","article-title":"Intensive blood pressure lowering in patients with malignant left ventricular hypertrophy","volume":"80","author":"Ascher","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacadv.2026.103096_bib29","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.jacc.2008.12.015","volume":"53","author":"Hancock","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacadv.2026.103096_bib30","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.2337\/dc17-0885","article-title":"Effect of intensive versus standard blood pressure treatment according to baseline prediabetes status: a post hoc analysis of a randomized trial","volume":"40","author":"Bress","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacadv.2026.103096_bib31","doi-asserted-by":"crossref","first-page":"e003613","DOI":"10.1161\/CIRCHEARTFAILURE.116.003613","article-title":"Effect of intensive blood pressure treatment on heart failure events in the systolic blood pressure reduction intervention trial","volume":"10","author":"Upadhya","year":"2017","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacadv.2026.103096_bib32","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.2337\/dc19-1074","article-title":"Prediabetes and risk for cardiovascular disease by hypertension status in black adults: the Jackson Heart Study","volume":"42","author":"Hubbard","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacadv.2026.103096_bib33","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.jdiacomp.2007.10.001","article-title":"The incidence of heart failure among nondiabetic patients with and without impaired fasting glucose","volume":"23","author":"Nichols","year":"2009","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.jacadv.2026.103096_bib34","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1161\/01.CIR.0000091339.70120.53","article-title":"Inflammation in the prediabetic state is related to increased insulin resistance rather than decreased insulin secretion","volume":"108","author":"Festa","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.jacadv.2026.103096_bib35","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.jchf.2020.10.013","article-title":"Biomarker-Based risk prediction of incident heart failure in pre-diabetes and diabetes","volume":"9","author":"Pandey","year":"2021","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jacadv.2026.103096_bib36","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1111\/dom.15557","article-title":"The effect of glucagon-like peptide-1 receptor agonists on cardiac function and structure in patients with or without type 2 diabetes mellitus: an updated systematic review and meta-analysis","volume":"26","author":"Zhang","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jacadv.2026.103096_bib37","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(22)01429-5","article-title":"SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials","volume":"400","author":"Vaduganathan","year":"2022","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.jacadv.2026.103096_bib38","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacadv.2026.103096_bib39","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/0735-1097(94)00371-V","article-title":"Electrocardiographic identification of increased left ventricular mass by simple voltage-duration products","volume":"25","author":"Okin","year":"1995","journal-title":"J Am Coll Cardiol"}],"container-title":["JACC: Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X2600517X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X2600517X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T23:27:22Z","timestamp":1792020442000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772963X2600517X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":39,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2772963X2600517X"],"URL":"https:\/\/doi.org\/10.1016\/j.jacadv.2026.103096","relation":{},"ISSN":["2772-963X"],"issn-type":[{"value":"2772-963X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prediabetes, Malignant Left Ventricular Hypertrophy, and Risk of Incident Heart Failure Among Hypertensive Adults","name":"articletitle","label":"Article Title"},{"value":"JACC: Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacadv.2026.103096","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}],"article-number":"103096"}}